From Retrospective Reporting to Proactive Prediction: AI and Genomics Reshaping the Antimicrobial Resistance Defense Line
Background
Antimicrobial Resistance (AMR) is a critical health threat undermining the foundations of modern medicine. Existing surveillance systems have remained reactive, relying on post-hoc reporting after culturing resistant bacteria from clinical settings and testing drug susceptibility. This often leads to missing the window for transmission prevention, as the reality of resistance is only identified after it has spread through communities or ecosystems. Overburdened healthcare systems and insufficient diagnostic infrastructure further widen the time lag in statistical aggregation.
Ecosystem disturbances due to climate change, localized armed conflicts, and large-scale population movements are twisting infectious disease transmission paths in unpredictable directions. In low- and middle-income countries, deep statistical gaps persist due to a lack of laboratory equipment and specialized personnel. This is why critics point out that traditional culture-based epidemiological investigations cannot keep pace with the rapid mutation rate of surging multidrug-resistant bacteria.
Even accumulated resistance information has been left fragmented across human, animal, and environmental sectors. A paradigm shift is urgently needed to capture warning signs in advance and deploy preemptive defenses.
Key Findings
This research presents a methodology to transition from a retrospective reporting system to proactive predictive intelligence by combining Artificial Intelligence (AI), Whole-Genome Sequencing (WGS), and metagenomics. Thanks to next-generation sequencing technologies that can read entire microbial communities, it is now possible to identify Antibiotic Resistance Genes (ARG) at the genomic level, even for pathogens that are difficult to culture. By integrating Machine Learning (ML) algorithms, researchers can precisely pinpoint unknown resistance mutations and potential transmission pathways by synthesizing sequence patterns and clinical information.
In particular, the utility of wastewater-based genomic epidemiology in environmental surveillance has been proven. The study explains that analyzing wastewater treatment plant samples using metagenomic technology can capture trends in the spread of resistance genes weeks before clinical diagnoses. This provides a shield for early warnings at the population and ecosystem levels. However, current digital surveillance networks show limitations, remaining confined to individual sectors or relying on short-term project grants. A unified 'One Health' platform encompassing humans, animals, and the environment has not yet reached the operational stage anywhere in the world.
The researchers also presented a blueprint for non-antibiotic therapeutic pipelines to overcome drug resistance. Bacteriophages, which specifically lyse target bacteria, and CRISPR-based antimicrobials, which precisely target resistance genes, are emerging at the forefront. Antimicrobial Peptides (AMP) that destroy bacterial cell membranes, microbiome normalization technologies, and nanomedicines are also listed among the next-generation weapons. Host-directed therapies, photodynamic therapy, and resistance-preventing vaccines are also identified as essential components of the core portfolio.
Significance and Outlook
The predictive platforms led by AI and genomic epidemiology are gaining attention as the key to bridging the speed gap between antibiotic development and public health response. Considering that developing new drugs takes over 10 years and massive costs, establishing early warning networks is an economical way to extend the effective lifespan of existing drugs. Non-antibiotic alternatives, such as phage therapy and CRISPR antimicrobists, are accelerating their entry into clinical trials as customized treatments targeting multidrug-resistant superbugs. The pharmaceutical industry also gains an opportunity to shift research directions toward targeted biotherapeutics, reducing the burden of developing high-failure-rate broad-spectrum antibiotics.
However, significant hurdles remain before these research achievements lead to actual commercialization. High-cost sequencing equipment and data analysis computing resources are concentrated in some developed nations; if regional imbalances in data collection are not resolved, the predictive power of AI models may remain halved. Differences in international surveillance data sharing regulations and licensing standards are also identified as immediate challenges to be addressed. A practical quarantine network capable of confronting borderless microbial threats can only be completed if supported by multidisciplinary collaborative systems and stable public financial support.
Antimicrobial resistance (AMR) surveillance is increasingly strained by interconnected global crises, i.e., pandemics, climate change, armed conflicts, population mobility, and health inequalities, that disrupt healthcare delivery, diagnostic capacity, and laboratory infrastructure. In parallel, artificial intelligence (AI), machine learning, whole-genome sequencing, metagenomics, and digital surveillance offer the potential to shift from reactive reporting to predictive intelligence that anticipates resistance threats, although current implementations remain sector-specific, retrospective, and project-funded. Environmental surveillance, particularly wastewater monitoring coupled with genomic epidemiology, provides early warnings at population and ecosystem levels. The future integration of AI across human, animal, and environmental sectors could enable unified One Health intelligence; no such integrated platform is currently operational. This review focuses primarily on bacterial AMR. It examines how global drivers strain surveillance, how genomic, metagenomic, digital, and AI-enabled technologies reshape AMR detection and prediction, and the emerging non-antibiotic therapeutic landscape, including bacteriophage therapy, Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-based antimicrobials, antimicrobial peptides, microbiota-directed interventions, nanomedicine, host-directed therapies, photodynamic therapy, and vaccines. It then explores how these innovations can be integrated within a One Health framework to support coordinated global preparedness. Addressing the AMR crisis will require not only technological innovation but also equitable implementation, interdisciplinary collaboration, and resilient systems.
The integrated surveillance system and non-antibiotic treatment models discussed in this study provide concrete application points for infection control departments in medical institutions and quarantine authorities. If wastewater pipeline monitoring in large hospitals is linked with genomic analysis, the influx or hospital-wide outbreaks of Carbapenem-Resistant Enterobacterales (CRE) in intensive care units can be rapidly detected even before clinical specimen confirmation. If AI mutation prediction algorithms are introduced to diagnostic laboratories, the time required for drug susceptibility testing—which typically takes more than two days—can be reduced to within a few hours, dramatically increasing the accuracy of initial prescriptions.
In the field of drug development, this serves as a guideline to increase the clinical success rate of non-antibiotic therapeutic pipelines. When designing synthetic antimicrobial peptides or CRISPR delivery vehicles, it becomes possible to implement strategies that preemptively block the potential for target bacteria to evade mutations by cross-verifying with wastewater and clinical genomic databases.